E*TRADE Financial Corporation (NASDAQ:ETFC) slipped over -1.04% at $49.4. E*TRADE Financial Corporation has 273.44 million shares outstanding, and in the last trade has seen ATR around 0.96. The volume of ETFC witnessed a shift from 2.93 million shares, based on a 50-day average, to 2.21 million shares.
In the most updated research from a number of analysts on Wall Street, the company gets 12 Buys and 0 Sell among 16 analysts. E*TRADE Financial Corporation (NASDAQ:ETFC) hasconsensus analyst target price is $48.94. That gives us a street projected return of -0.93%. If the published price targets set by E*TRADE Financial Corporation analysts have any power to influence the stock’s share price, the highest price target set for ETFC is $56.
E*TRADE Financial Corporation most recently reported earnings per share (EPS) of $0.55 for the September 2017 versus $0.51 in the same quarter last year, representing 8% growth. Analysts had predicted $0.51. Revenue during the quarter was $599 million, representing 23% growth from $486 million in year-ago quarter. The company’s quarterly EPS surprised Wall Street by as much as 8% to the upside in its last earnings announcement, so investors should note this tendency when assessing consensus estimates.
On a similar note, analysts expect EPS of $0.59 in December 2017 quarter and $0.57 in March 2018 quarter, representing 37.21% and 18.75% growth, respectively. They expect this year’s earnings to rise 22.16% year-over-year to $2.26, followed by 14.6% growth in the next year to $2.59.
Shares of Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) traded down -13.5% in the last session while performance was up 1.73% in the last five days. The stock’s last price was lower from the average trading price of 50 days recorded at $1.83 while enlarging the period to 200 trading days, the average price was $3.15. Currently, 11.88 million total shares are owned by the public and among those 9.61 million shares have been available to trade. The percentage of shares being held by the company management was 18.2% while institutional stake was 8.8%.
Cyclacel Pharmaceuticals, Inc. (CYCC) has risen 15.62% since then. But since then, those gains have faded by -84.13%. CYCC has risen 4.22% in the 1-month period.
E*TRADE Financial Corporation has a beta of 3.68, offering the possibility of a higher rate of return, but also posing more risk. The portion of a company’s profit allocated to each outstanding share of common stock was -$2.47 a share in the trailing twelve months. It last reported revenues of $280000 and EPS of $Last 4 Weeks for the September 2017, representing -45% top-line growth and EPS growth.
Looking forward, the company’s quarterly earnings in the three months through December 2017 and in the quarter ending March 2018, reflecting -144883% and -262995% growth, respectively. For the full year, analysts expect earnings to decline -35.71% yoy to -$2.25. Next year this decline will reach -30.22% to attain -$1.57.